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CHAPTER 1: GENERAL INTRODUCTION 
G proteins 
There are two classes of GTP binding proteins (G proteins) -- heterotrimeric and 
small G proteins. Heterotrimeric G proteins consist of three subunits: a , p, and y. The alpha 
subunits bind OTP and catalyze the enzymatic reaction to return it to GDP. Upon activation 
by GTP, the alpha subunit dissociates from the beta/gamma subunit and both are able to acti-
vate their downstream effectors. (36) The small G proteins are monomeric and able to both 
bind GTP and downstream effectors. The first small G proteins discovered, and some of the 
best studied, were the mammalian Ras proteins (K-Ras, H-Ras and N-Ras). Other members 
of the Ras super-family include Rho, Ran, Rab and Sar/Arf. 
Properties of G proteins 
All G proteins cycle between an activated state, with GTP bound, and an inactive 
state, with GDP bound. While G proteins are able to undergo this cycle without assistance, 
the rate is so slow that help is often required to allow the proteins to be functional in living 
cells. An inactivated G protein must interact with a guanine nucleotide exchange factor 
(GEF) in order to exchange its GDP for a GTP. The binding of the GTP causes a conforma-
tional change in the protein, allowing it to interact with its downstream effectors. In the 
course of time, the intrinsic GTPase activity will inactivate the protein. Often, especially in 
small G proteins, the intrinsic rate is too slow, so GTPase activating proteins (GAPs) catalyze 
the cleavage of the phosphate bond to form GDP by insertion of an arginine side-chain into 
the active site of Ras (1). By this rapid switching between GIP and GDP states, G proteins 
are able to pass signals from their upstream activators to their downstream effectors. 
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Most small G proteins, including K-, H-, and N-Ras, contain signals at their C-
terminus that lead to posttranslational modifications. These modifications include the addi-
tion of lipid moieties (the isoprenoid farnesyl or geranylgeranyl, and the fatty acid palmitate) 
that help to attach the small G proteins to the membrane. Even though these specific moie-
ties are not required (10), membrane localization is necessary for activity of Ras (37). 
Ras subfamily 
In humans and other mammals, there are three different genes that code for the small 
G protein Ras (H-Ras, K-Ras, and N-Ras), that after translation and alternative splicing form 
four different proteins (H-Ras, K-RasA, K-RasB, and N-Ras). Viral forms ofH-Ras and K-
Ras were discovered in the 1960' s (12) and afterwards, as altered forms of cellular Ras pro-
teins in human tumors (33). Further research has shown that Ras is expressed in all eukaryo-
tes, including yeast and insects, and in most mammalian cell types (11). The genes for Ras 
proteins are mutated in about 90% of human pancreatic cancers, 35% of lung cancers, about 
60% of thyroid cancers, and to a significant level in many other kinds of cancer (11 ). Ras 
GTPase activity is almost always the mutational point in human tumors (11 ). One such mu-
tation is a glutamine to leucine mutation at the 61 st amino acid (AA). 
Ras homology 
Ras shares 40-50% homology with its other family members, such as Rap and Ral 
(12). Between the four Ras proteins, there is a high level of homology-- about 85% sequence 
identity (Figure 1.1 ). The N-terminus, especially the GTP binding domain, is extremely con-
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served, while the C-terminus contains most of the variation in a domain called the hypervari-
able region (HVR). Within the HVR is the signal sequence for membrane localization called 
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Figure 1.1 - Comparative structures of Ras proteins with various domains labeled. Yellow and cyan indicate a 
different amino acid than is found in H-Ras. Cyan also indicates the hypervariable region (HVR). The CAAX 
box is the signal sequence for membrane localization. 
Cellular processing of Ras 
In order for Ras to become active, it must be posttranscriptionally modified, although 
the modifications differ depending on the C-terminus. All Ras proteins contain a CAAX se-
quence, this is a sequence specific signal instructing famesyl transferase to add a famesyl 
moiety to the cysteine (26). The AAX portion of the sequence is then cleaved by a protease 
and replaced by a carboxymethyl group on the prenylated cysteine's carboxyl group. (26) 
After this point, there are no further modifications to K-Ras4B. N-Ras and H-Ras receive 
one or two palmitates respectively, on cysteines near the CAAX motif, through a thioester 
linkage. Palmitoylation is a readily reversible reaction, a dynamic property which may be 
important for Ras signaling (20). 
The above-mentioned posttranslational modifications are necessary for proper local-
ization of Ras proteins. All native Ras proteins function at the cytoplasmic side of the 
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plasma membrane, although the path taken to arrive at the membrane is different. K-Ras4B, 
since it receives no further modifications, goes straight out to the plasma membrane through 
an unknown, golgi-independent pathway. However, both H-Ras and N-Ras appear to adhere 
to the cytoplasmic surface of vesicles that traffic from the endoplasmic reticulum (ER) 
through the golgi network and onwards to the plasma membrane. (26) Originally it was be-
lieved that signaling could occur only at the plasma membrane, but recent evidence indicates 
that Ras might be able to signal from endomembranes ( 5) 
Biological effects of activated Ras 
Once activated, Ras causes different biological effects in diverse cell types. In 
NIH3T3 mouse fibroblasts, activated H-Ras will cause transformation (31 ). This is evi-
denced by a spindle-shaped appearance and tumor-like properties, including a loss of contact 
inhibition of growth, permitting foci formation. Contact inhibition is a property of untrans-
formed cells that tells the cells to cease cellular replication upon close contact with neighbor-
ing cells. Untransformed cells also need to adhere to a solid surface, unlike their transformed 
counterparts that gain the ability to grow suspended in agar. 
In adrenal pheochromocytoma (PC-12) cells, the expression of activated Ras results 
in yet another phenotype. The cells will differentiate, which can be seen by the outgrowth of 
neurites. The neurites formed by Ras activation are comparable to those caused by nerve 
growth factor (NGF). An average of two neurites can be found on PC12 cells exposed to 
NGF, extending thin and straight, away from the cell. (4) 
Ras effectors 
To cause these diverse effects in cells, Ras must interact with several different down-
stream effectors. The two principle effectors of Ras are the serine-specific protein kinase Raf 
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and phosphatidylinositol 3- kinase (PBK). Activation of Raf is the beginning of a signal 
cascade involving mitogen-activated protein kinase (MAPK) and leading to the regulation of 
gene transcription (35). The activation of PBK also causes a different signaling cascade to 
occur, that results in the formation of 3' phosphorylated phosphatidylinositols and their re-
cruitment to the plasma membrane and subsequently the activation of other proteins, such as 
Akt and Btk (12). 
In addition, Ras interacts with many other proteins that are important for its regula-
tion, such as GEFs and GAPs. There are a number of GEFs that will bind to and activate Ras 
proteins. The GEFs Sosl and RasGRPl interact with all types of Ras. Other GEFs are more 
specific and will only interact with particular Ras proteins. For example, RasGRFl is able to 
activate H-Ras, but does not interact with N- or K-Ras. GAPs are also important regulators 
of Ras. The best-studied GTPase activating protein for Ras is p120 RasGAP. (12) 
Detergent resistant membranes 
The plasma membrane was once thought to have the properties of a fluid mosaic (28). 
Proteins and lipids were able to freely move throughout the plane of the membrane, proteins 
floating in a sea of lipid. This model has recently been shown to be incomplete, due to the 
discovery of different microdomains within the membrane (21 ). These domains contain lip-
ids that resist extraction by cold detergent, and hence are known as detergent resistant mem-
branes (DRMs). These domains are also known by many other names, including lipid rafts, 
glycolipid-enriched membranes, and detergent insoluble glycolipid-rich domains. Many new 
discoveries are showing the importance of these domains for various cellular functions, in-
eluding cell adhesion ( 15), synaptic transmission (34), viral budding (22), and signal trans-
duction (6). 
Properties of DRMs 
The existence of detergent resistant microdomains was first proposed during the 
l 990 's (7). This indicated that DRMs had more structure, a liquid ordered phase, than the 
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sea of lipid they were floating in, which has earned them one of their common names: lipid 
rafts (14). A closer investigation of these regions indicated that DRMs seemed to be similar 
in composition to caveolae-- invaginations in the plasma membrane which were thought to 
mediate the transport of molecules across the membrane (29). In many cases DRMs are 
similar to caveolae, but cells that do not express caveolin may contain DRMs (13), so the two 
are not equivalent. 
Composition of DRMs 
The composition of DRMs differs dramatically from the remainder of the plasma 
membrane. In general the plasma membrane is made up of glycophospholipids and low lev-
els of cholesterol (21 ). In contrast, the major components of both DRMs and caveolae are 
sphingolipids, cholesterol, glycosylphosphatidylinositol (GPI) anchored proteins (8) and 
caveolin (Figure 1.2). The partitioning of sphingolipids and cholesterol to DRMs decreases 
their fluidity. Sphingolipids, whose tails are usually completely saturated, decrease the fluid-
ity by being able to pack more tightly than their non-raft counterparts, which are often un-
saturated (7). In addition to this, cholesterol is able fill in small gaps in between phosphol-
ipid head groups, and provide for the increased stability of DRMs and caveolae (21 ). 
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In many cell types, the most common protein in DRMs is caveolin. Caveolin is an in-
tegral plasma membrane protein between 21 and 24 kDa, the major component of caveolae. 
By binding to cholesterol, caveolin is able to selectively partition to the liquid ordered phase 
and act as a scaffold for other proteins, including signaling proteins (7). Among the signal-
ing proteins that interact and partition with caveolin, at least part of the time, are H-Ras, ade-
nylyl cyclase, heterotrimeric G proteins, as well as insulin and epidermal growth factor 
(EGF) receptors (29). 
Figure 1.2 - Cartoon of the plasma membrane containing a DRM. DRMs contain high amount of sphingolipids 
(blue) and cholesterol (red), as well as GPI linked proteins (purple). This differs significantly from the rest of 
the membrane (yellow glycolipids, with green transmembrane proteins) 
Isolation of DRMs 
Several techniques have been designed to isolate and study DRMs. One of the first, 
and most frequently used methods, is a density gradient. In this technique the membranes, 
which have been isolated from the whole cells, are placed in detergent (often Triton X-100) 
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at the bottom of a sucrose or a carbonate gradient and spun in an ultracentrifuge for at least 
14 hours. After this treatment, the resistant membranes are still intact and thus display the 
low density of all intact membranes by rising to the top of the gradient (2, 27). The detergent 
will disrupt nonresistant membranes, leaving the non-DRM proteins on the bottom of the 
gradient. Detergent extraction can also be used in immunofluorescence to detect DRMs in 
whole cells. 
An important question has been raised regarding DRMs: Are they just artifacts that 
arise from the detergent extraction itself (21 )? It is possible that by adding detergent to the 
cells that proteins and lipids are brought together that normally have no association with each 
other. To address this issue several studies have used non-detergent methods to isolate mi-
crodomains with a similar composition to DRMs (3 , 19). 
Several labs have now used a powerful technique to study DRMs and caveolae, called 
fluorescence resonance energy transfer (FRET). Using derivatives of GFP as acceptors and 
donors it is possible to measure distances between labeled proteins to determine their colo~ 
calization. Since FRET can only occur between molecules 10 nm or less apart, it is much 
more precise than standard microscopy. ( 18) 
RasandDRMs 
There is a lot of debate in the scientific community regarding Ras and its interactions 
with DRMs. Several different studies have shown that H-Ras does localize, to some extent, 
with DRMs (9). Ras has also been shown to directly interact with caveolin, thus providing a 
mechanism for the partitioning of Ras to DRMs (30). A model has been put forth suggesting 
Ras is associated with DRMs only while it is inactive and is released from these domains 
upon activation (23 ). 
Background of chimeric proteins 
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Since Ras may be found in DRMs, several questions can be asked. Is Ras able to sig-
nal when it is specifically localized outside of those domains? Is DRM localization neces-
sary for H-Ras to become active? Can Ras activators and downstream effectors locate Ras if 
it is not in a DRM? Does the activity of Ras, without an activating mutation, increase upon 
removal from DRMs? To answer these questions several different chimeric Ras proteins 
were studied. 
E1 infectious bronchitis virus chimera 
A chimeric, transmembrane H-Ras protein was designed during the late 1990's (16). 
This protein was created with the external and first transmembrane (TM) domains of the E 1 
protein from the avian infectious bronchitis virus (IBV) attached to a cytoplasmic domain 
consisting of either H-Ras wt (EHRwt) or H-Ras 61L (EHR61L). El is an N-terminally gly-
cosylated protein that is incorporated into the envelope of the virus. The El protein localizes 
to the cis-golgi in infected cells, but a Q-)> I mutation in the first transmembrane domain will 
allow the protein to be transported through the golgi network and out to the plasma mem-
brane (32). The specific localization of EHR within the plasma membrane, either in or out of 
DRMs, was unknown. 
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CD45 chimera 
CD45 is a tyrosine phosphatase that is expressed in human Band T cells. It is a vital 
regulator of receptors on the cells that control the immune system response to antigens. 
There are several splice variants, depending on which exon(s), if any, (A, B, or C) are ex-
pressed at the N-terminus of the protein. B220, the isoform of CD45 that was used to con-
struct the chimera with H-Ras 61L (CHR61L), contains all three exons. (25) 
With the goal of generating a non-DRM construct, CD45 was selected for the con-
struction of the chimeric Ras. The rationale for this was due to several previous studies that 
showed that CD45 does not localize to DRMs (17, 24). The making ofthis protein was simi-
lar to that of EHR proteins-- using the extracellular and transmembrane domains with a short 
linker between the TM and Ras. 
Purpose of chimeric Ras proteins 
By studying several different chimeric Ras proteins we desire to learn how Ras func-
tions outside of DRMs. By showing that the chimeric Ras proteins are or are not able to 
function outside of DRMs we will be able to better understand cellular localization of Ras. 
We may then be able to better explain its oncogenic properties. We will also be able to ex-
amine how its signaling differs from native and constitutively activate Ras. Similarities and 
differences in signaling between the chimeric Ras proteins and the constitutively activated 
Ras will provide insight as to how Ras typically interacts with DRMs. 
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Organization of thesis 
The general introduction found above gives background for all of the chapters of this 
thesis that follow. Both chapter 2 and chapter 3 are written in publication format. The sec-
ond chapter has been written in the format used by Molecular Cellular Biology and the third 
chapter has been written with the intent of submitting it soon to the same or comparable jour-
nal. I did all of the research and writing for the third chapter, except the focus assay experi-
ments in NIH 3T3 cells, which were done in Berthe Willumsen' s lab, University of Den-
mark, Copenhagen. The final chapter contains general conclusions that can be drawn from 
this research, as well as future directions. 
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CHAPTER 2: A TRANSMEMBRANE H-RAS WITH MINIMAL 
CELLULAR EXPRESSION 
Abstract 
A paper written in the format of Molecular Cellular Biology 
Jessica Price and Janice Buss 
H-Ras is a 21kD protein encoded by the H-ras human oncogene. While it is under-
stood that H-Ras must localize at a membrane, most commonly the plasma membrane, the 
precise localization is not well understood. Within the plasma membrane there are discrete 
regions that are known as detergent resistant membranes (DRMs ). The current debate is if 
H-Ras interacts with or localizes in DRMs. This study examines a transmembrane version of 
H-Ras that is to be specifically directed to non-DRM regions by the transmembrane and ex-
tracellular domains from CD45. The DNA was properly constructed and transfected into 
various cell lines but gave only minimal cellular expression. After optimizing many different 
cellular and experimental conditions it was determined that this particular non-DRM H-Ras 
construct is not expressed at useful levels. Further study will need to be done to determine if 
its non-DRM status causes the lack of expression. 
Introduction 
H-Ras (21kD) is an important member of a class of proteins called small G proteins. 
H-Ras, along with the other Ras proteins of the mammalian cell (K-Ras4A, K-Ras4B and N-
Ras), binds GTP in its active state. By the mechanism of its intrinsic GTPase activity and 
helper GTPase activating proteins (GAPs) it converts the GTP to GDP and thus becomes in-
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active. To then reactivate the protein guanine nucleotide exchange factors (GEFs) are then 
recruited to exchange the GDP for a GTP. While active, Ras initiates its signal cascades, 
thereby regulating gene expression and the cell cycle. The standard GDP/GTP cycle can be 
broken by certain mutations to the Ras protein, causing it to remain in the active, GTP-bound 
form. One such mutation is the Gln61Leu mutation, in the GTP binding domain. (5) 
In recent years it has been shown that the plasma membrane is not a random con-
glomeration of lipid and protein as was once predicted, but there are discrete domains within 
the membrane (8). These domains, which can be isolated using their detergent (Triton X-100 
or Brij) resistant feature , contain elevated levels of cholesterol and sphingolipids both of 
which contribute to their less fluid state ( 4). There is still much controversy over the nature 
of these detergent resistant membranes (DRMs) and their role in the cell (12) . Recent evi-
dence indicates that they may play a role in signal transduction by acting as a platform where 
signaling proteins can congregate (3). H-Ras is hypothesized to interact with DRMs, al-
though its exact mechanism is still being debated (1 , 9). 
Seeking to better understand the importance of the interaction between H-Ras and 
DRMs we decided to examine the biological implications of prohibiting H-Ras from interact-
ing with DRMs. To achieve this goal we made three important modifications to H-Ras. The 
first was the addition of the extracellular and transmembrane domains of CD45 to the N-
terminus of Ras. CD45 has been known to localize outside of DRMs (7, 10), thus making it 
an excellent choice for these experiments. The second modification was to the C-terminus of 
Ras. There are three cysteines that each receives either a famesyl or a palmitate upon cellu-
lar posttranslational modification ofH-Ras (13). These lipids are the factors that normally 
cause H-Ras to be localized at the plasma membrane (13). In order to ensure that these lipids 
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do not influence the localization of the new transmembrane protein, these cysteines were all 
mutated to serines, thus eliminating the lipid binding. The third change was the previously 
mentioned Q6 l L mutation. 
Materials and methods 
DNA 
The construction of CHR61 L began with CD45 cDNA of the mouse B220 isoform of 
the CD45 protein, obtained from Bart Sefton (Salk Institute). Human H-Ras has been modi-
fied by the following mutations: Q61L, causing constitutive activation, C181S, C184S and 
Cl86S, preventing posttranslational modification of protein by isoprenoids and thus eliminat-
ing endogenous membrane binding. Delta CD45 (~CD45) is defined as the external and 
transmembrane domains of full length CD45. B220 cDNA in pBluescript (Stratagene) was 
cut with Cla I. The 3' overhang was filled in using a Klenow reaction kit (Promega), and 
then it was cut with Xho I. pcDNA3 (lnvitrogen) was cut using EcoR V, a blunt cutter, and 
Xho I, and was then ligated to B220 cDNA that had been prepped in the above-mentioned 
manner. While the Klenow reaction should have destroyed the Cla I site, upon ligation with 
the EcoR V blunt end the Cla I site was inadvertently recreated. This is not an issue for fur-
ther cloning due to its Dam methylation sensitive nature. 
To generate ~CD45 , PCR was used to engineer a Cla I site, a stop codon, and a Xho I 
site after the transmembrane domains of B220. Based on the research of Hart and Donaghue 
(6) Ras was specifically placed 42 base pairs after the transmembrane in order to ensure it 
was not too proximal to the plasma membrane. The sense oligo used was 5' CgA AA TT AA 
TAC gAC TCA CT AT Ag 3' and the antisense oligo was 5' CgC gCg CTC gAg CgC gCg 
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CgC TCA ATC gAT ATT gCT ggA TCT TIT CIT gCg 3' . The ~CD45 PCR product was 
then inserted into pcDNA3 using Xho I and EcoR I. 
PCR was also performed on H-Ras to engineer Cla I and Xho I sites in the proper lo-
cations, 5' and 3' respectively, to attach it to ~CD45. The sense oligo used for the PCR was 
5' CgC gCg ATC gAT ACA gAA TAC AAg CTT gTg gTg g 3 ' and the antisense oligo was 
5' CTA gAT gCA TgC TCg AgT CA 3' . Ras and ~CD45 were both cut with Cla I and Xho 
I and were ligated together. 
Other DNAs used include GFP H-Ras 61L, EHR61L (see Chapter 3, from B. Wil-
lumsen, University of Denmark), H-Ras Ext61L (H-Ras 61L with a polybasic tail after the 
CAAX box and known to localize in DRMs (2)). 
Cell culture 
NIH3T3 and Cosl cells were grown in DMEM (Gibco) + 10% calf serum. 293T 
cells were grown in DMEM + 10% fetal bovine serum. PC-12 cells were grown in RPMI 
(Gibco) + 10% heat inactivated horse serum + 5% fetal bovine serum. All cells were grown 
in 5% C02 except 293T cells, which were grown in 10% C02. Stable NIH3T3 cell lines 
were formed one of two ways. The first method was direct application of lOOOug/mL G418 
to the cells that had been transfected with the desired construct in a neomycin resistant vector 
(pEGFP-C3 for GFP H-Ras 61L and pcDNA3 for other Ras). The second involved a co-
transfection of the appropriate DNA with plRESpuro, an empty vector containing the gene 
for puromycin resistance. Puromycin was then added at a concentration of 1 µg/mL. 
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Antibodies 
Antibodies used for western blotting and immunofluorescence are: Ras 146-3E4 
(Quality Biotech); Ras Y13-238 (Santa Cruz); Ras Yl3-172 (C. Der, University ofNorth 
Carolina); anti-caveolin (Transduction Laboratories); CD45 M-20 (Santa Cruz); CD45 RA3-
6B2 (Santa Cruz); CD45 35-Z6 (Santa Cruz), CD45 13/2.3 (B. Sefton, Salk Institute). Ap-
propriate secondary antibodies were used (Molecular Probes). 
Transfection 
Most transfections of CHR61 L were performed using Superfect (Qiagen), with 1.6µg 
of DNA used in each well of a 12-well plate. All transfections in PC-12 cells were per-
formed using Lipofectamine (Invitrogen), with 0.8µg of DNA used per well of a 12-well 
plate. Other transfection reagents used to improve protein expression include Effectene 
(Qiagen), Perfectin (Gene Therapy Systems) and Lipofectamine Plus (lnvitrogen). These 
were all used according to their manufacturer' s directions. 
lmmunofluorescence 
All cells were grown on coverslips coated with poly-L-lysine (1 OOµg/mL) and/or fi-
bronectin (50µg/mL) in PBS. Cells were washed with PBS and then fixed with 4% parafor-
maldehyde for 5 minutes on ice. Cells were then permeabilized with cold methanol for 30 
seconds. Formaldehyde was quenched (1 % milk, 150mM NaOAc in PBS, pH7) and cells 
were washed (1 % milk in PBS) before incubating in primary antibody (diluted 1 :400 in wash 
buffer). Secondary antibodies were also diluted (1 :700) in wash buffer. After rinsing, cells 
were mounted on microscope slides using 4µ1 Vectashield (Vectorlabs). Variations on this 
protocol include the length of time for each step of the procedure and using 5% goat serum 
with 0.4% BSA in PBS as a blocker instead of milk containing solutions. 
In vitro translation and western blot 
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Translation was performed in vitro using the TNT T7 Quick Coupled Transcrip-
tion/translation System (Promega). Added to the kit were I µg DNA and 10 µCurie [S35] 
methionine and then the samples were incubated at 30°C for 90 minutes. These samples or 
cellular lysates were run on SDS-PAGE (sodium dodecylsulfate polyacrylamide gel electro-
phoresis) gels. The gels were transferred to PVDF membrane and were either exposed over-
night by autoradiography or probed with the appropriate antibody and detected by chemilu-
minescence (ECL ). 
Results 
Construction of CHR61 L 
The CD45:H-Ras 61L (CHR61L) chimeric protein was designed from full-length 
cDNA of the B220 isoform of CD45 in the pcDNA3 vector. A truncated form of CD45, 
called ~CD45, was created containing only the extracellular and transmembrane domains of 
CD45. After engineering appropriate restriction sites it is possible for H-Ras to be inserted 
just downstream from the transmembrane domain. Figure 2.1 A shows the plasma map of 
CHR61L in pcDNA3, while Figure 2.IB gives an illustration ofCHR61L attachment to the 
plasma membrane. 
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Figure 2.1 - (A) Plasmid map of CHR61L in pcDNA3. (B) Depictions of antibody epitope information, when 
known , of full length CD45 , H-Ras 61L, and CHR61L proteins interacting with the plasma membrane (adapted 
from ( 11)). 
In vitro translation 
To confirm the construction of CHR61L an in vitro system was used to express the 
protein. The rabbit reticulocyte both transcribed and translated the DNA to make the appro-
priate protein. As indicated in the Materials and Methods, S35 labeled methionine was added 
to the system incorporation in to the protein, thus providing a means to detect the protein. 
The samples were then run on a SDS-PAGE gel and detected via autoradiography. Expres-
sion of all CD45 constructs, full length CD45, ~CD45, and CHR61L, as well as an H-Ras 
positive control were assayed (Figure 2.2A). Clean, well-defined bands were detected at the 
expected sizes for all constructs. These results indicate that CHR61L and its precursors were 
correctly made and able to be expressed. It should be noted that even in the in vitro system 
the expression of all CD45 constructs, including CHR61 L, had much lower expression than 
the Ras positive control. The cause of this decreased expression remains unknown. 
In order to ensure that the proper, full-length proteins were translated the membrane 
was probed with a Ras antibody (Figure 2.2B). Once again clean bands were 
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Figure 2.2 - Lanes in both A and B: 1) ~CD45 2) full length CD45 3) CHR61L 4)H-Ras Ext61 L (a version of 
H-Ras with a polybasic tail). (A) TNT samples of ~CD45, CD45 , CHR61L and H-Ras Ext61L were run on a 
SDS-PAGE gel and detected via autoradiography. (B) The membrane was then probed with the Ras 146 anti-
body, which was able to detect all Ras containing constructs. 
detected at the proper sizes in lanes 3 and 4. By using the Ras 146 antibody it was also pos-
sible to conclude that there was no premature termination of translation, since its epitope is 
located at the C terminus of Ras (Figure 2. lB). This evidence, as well as the autoradio-
graphic data, conclusively demonstrates that proteins of the proper size and content can be 
made from the DNA constructs. Attempts were also made, unsuccessfully, to detect the 
CD45 containing proteins using CD45 antibody (data not shown). 
Detection via western blot 
Western blot was used to undertake the detection of CHR61L in vivo. Plasmids con-
taining the CD45 or CHR61L gene were transfected into NIH3T3 cells. Cells were lysed, 
run on a SDS-PAGE gel, transferred to PVDF and blotted with the CD45 antibody 35-Z6 
(see figure 2. lB for epitope information). While, CD45 could be detected in commercially 
available Jurkat cell lysate (Figure 2.3, lane 1), it was not found in the NIH3T3 cells that had 
been transfected with either full length CD45 (Figure 2.3, lanes 2-4) or with CHR61L (Figure 
2.3, lanes 5-7). 
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Figure 3 - Western blot probed with CD45 antibody 35-Z6 containing commercially available Jurkat cell lysate 
in lane I , CHR61L NIH3T3 cell lysate in lanes 2-4, and CD45 NIH3T3 ccll lysate in lanes 5-7 . 
In addition to attempting to detect CHR61L with the CD45 antibody 35-Z6, several 
other antibodies were, directed to CD45, as well as the Ras domain, used (see Materials and 
Methods and Figure 2.lB). However, none of these improved the detection of CHR61L. 
Additional attempts were made in order to improve protein expression and detection. These 
variables included using different cell types (NIH3T3, Cosl, 293T), transfection reagent (Su-
perfect, Lipofectamine, Effectene, Perfectin, Lipofectamine Plus) , adjusting concentrations 
of antibodies, altering the blocker and antibody diluent (milk, casein, BSA and TTBS), and 
incubation time of membrane in antibody. Also, cotransfection of CHR61L with full length 
CD45 or with H-Ras was performed with no increased expression of CHR61L. While some 
of these variations gave slightly better results, the overriding observation was low, sporadic 
detection of any CD45 construct. 
Detection via immunofluorescence 
Another method used to detect CHR61L in vivo was immunofluorescence. This 
method allows indirect visualization of protein in intact cells using antibodies. Initial at-
tempts at detecting CHR61L in NIH3T3 cells were not very successful, thus many different 
variables were examined in hopes of improving the transfection efficiency and expression. 
These variables included changing the cell type (Cosl, PC-12, and 293T cells), immunofluo-
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rescence protocol (different time lengths, blockers, etc), transfection reagent (including Ef-
fectene, Superfect, Lipofectamine, Lipofectamine Plus, and Perfectin), amount of DNA per 
well and antibody (both to the CD45 and the Ras portions of CHR61L). A second means of 
verifying transfection efficiency is by transfecting PC-12 cells with activated Ras and look-
ing at their differentiation. CHR61 L did not cause the differentiation that one would expect. 
This could be because of its non-DRM characteristic, of its low expression, or toxicity. 
Many of the changes to the above mentioned variables were not advantageous to the 
expression of CHR61L, although a few were. Antibodies to the Ras portion of the chimeric 
protein were much better at detecting CHR61 L than antibodies to the external domain of 
CD45; the Ras 172 antibody gave the strongest signal. Superfect led to the strongest expres-
sion and made the cells the least sick. Cotransfections of CHR61 L with H-Ras wt or with 
full length CD45 were also performed, although no better results were attained. Overall there 
were small successes in detecting CHR61 L (Figure 2.4), but they were not large enough to 
draw any conclusions as to the biology or biochemistry of the protein. 
Figure 2.4 - Images were taken by confocal microscopy of one of the few (A) NIH3T3 and (B) Cos 1 cells 
brightly expressing CHR6 l L. Green staining was done using Ras 172 antibody and red staining was done using 
an anti-caveolin antibody. 
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Stable cell lines 
In an effort to increase the percentage of NIH3 T3 cells expressing CHR61 L, they 
were put under selection using the antibiotic 0418, resistance to which is provided by the 
ned gene in the pcDNA3 plasmid. Although there were some cells expressing CHR61 L just 
after transfection, no cells were expressing the protein after several weeks of selection. This 
seems to indicate that CHR61 L is at least somewhat toxic to the cells, since they found some 
means to resist the antibiotic without expressing the desired protein. 
A second method of selection was also used, which involved cotransfecting CHR61 L 
with the empty vector pIRESpuro, thereby conferring puromycin resistance to transfected 
cells. Puromycin was added to the media and several weeks later the cells were fixed and 
visualized, either by autofluorescence ( GFP61 L) or immunofluorescence ( CHR61 L, 
EHR61L) to check percentage of cells expressing protein. This second selection method was 
more successful, but when compared to stable cells lines from other Ras constructs the signal 
was extremely dim and with only a minimal number of cells were expressing the protein 
(Figure 2.5). 
Discussion 
Several different techniques were used to study the in vivo expression of CHR61 L 
and its CD45 precursors. After much work and optimization of multiple parameters the de-
tectable expression of these proteins remained minimal. As shown by the rabbit reticulocyte 
system this low expression was not due to errors in the construction of the protein. Therefore 
either the CHR61 L protein conformation was altered beyond recognition or the protein has 
mild to high level of toxicity in the cells. 
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Figure 2.5 - NIH3T3 cells after being under Puro selection for 1 month. CHR61L is still expressing protein of 
minimal portions when compared to EHR6 l L (see Chapter 3) and GFP61L. 
It seems reasonable that there is some level of toxicity conferred by CHR6 l L to the 
cells. There are two possible sources of this toxicity. The first is that CD45, which is not 
natively found in any of the cell lines studied, was toxic and therefore the CD45 chimeric 
protein was also toxic. The second option is that the non-DRM status of the chimeric protein 
resulted in the reduced health of the cells. Based on the data obtained thus far it is impossi-
ble to decide which possible source is correct, although since full length CD45 was also un-
detectable in vivo the former options seems more plausible. Further testing must be done us-
ing a different non-DRM protein to determine the biological effects of Ras plasma membrane 
distri bu ti on. 
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CHAPTER 3: TRANSFORMATION AND DIFFERENTIATION 
BY ACTIVATED, NON-ORM H-RAS 
Abstract 
A paper to be submitted to Molecular Cellular Biology 
Jessica Price, Berthe Willumsen, Janice Buss 
H-Ras, a small G protein, can activate several downstream effectors and cause diverse 
effects in the cell. These effects include cell cycle and gene transcription regulation. In or-
der to produce these effects H-Ras must localize at the plasma membrane via three lipid 
modifications, although its precise location, in or outside of detergent resistant membranes 
(DRMs), is still being debated. A transmembrane Ras (EHR wt or EHR61L, a continuously 
activated version) was designed to localize to the plasma membrane in a lipid-independent 
manner. Both EHR proteins were found, by detergent extraction, to be located outside of 
DRMs. Based on this localization, the question was asked if Ras would still be able to find its 
proper downstream effectors. EHR6 l L causes both transformation of 3 T3 cells and diff eren-
tiation of PC-12 cells, in a similar manner to normal activated H-Ras. The rates of cell and 
neurite growth caused by EHR61 L seemed to be slower than its lipid modified counterpart. 
EHRwt, while being localized in non-DRMs, does not become activated in either cell type. 
Introduction 
H-Ras, a 21kDa membrane bound protein, is a founding member of a subclass of 
small G proteins. Small G proteins are part of a larger class of proteins called GTP binding 
proteins (G proteins), a grouping that also contains heterotrimeric G proteins. All small G 
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proteins share common characteristics and H-Ras is no exception. These properties include 
the ability to bind GTP and thus become activated, a low level of GTPase activity to return 
the protein to an inactive state and the ability to activate several different signaling cascades 
(18). 
An understanding of the downstream effectors of a protein is vital when examining its 
biology. H-Ras activates many different pathways in cells, including several that lead to cell 
growth (7), at least one that causes differentiation of nerve cells and at least one that leads to 
apoptosis (6). While H-Ras is able to activate all of these pathways, they are difficult to ex-
amine unless there is an activating mutation in the protein. Mutations of this sort are often 
found in the GTP binding domain and prohibit the conversion of GTP to GDP, leaving the · 
protein in a continuously activated state (6). One such mutation is a glutamine to leucine 
switch at position 61. 
Detergent resistant membranes (DRMs) are defined as domains within the plasma 
membrane that have a different composition and less fluidity than the rest of the plasma 
membrane (10). DRMs contain high levels of sphingolipids and cholesterol, both of which 
decrease the fluidity of these domains (4). The protein composition of DRMs is also differ-
ent from the remaining PM. DRMs often contain a structural protein called caveolin ( 16) and 
many proteins that are anchored to the membrane via glycosylphosphatidylinositol (GPI) 
(15). There are also many different signaling proteins that have been shown to interact with 
DRMs, lending to the idea that DRMs may serve as signaling platforms (3). 
There has been a lot of study recently regarding Ras and DRMs. There is a signifi-
cant amount of evidence showing that Ras does interact with DRMs, although to what extent 
remains unknown (5, 9, 10). A recent model suggested by John Hancock et. al states that 
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Ras associates with DRMs only while its inactive and upon activation it repartitions to non-
DRMs (14). H-Ras has also been shown to interact with caveolin, a major DRM component 
of some cell types (17). 
These studies bring up several questions. Is it necessary for H-Ras to localize to 
DRMs in order to be activated? Must H-Ras associate with DRMs at all? What are the con-
sequences of Ras being exclusively localized in DRMs? Could H-Ras be active and function 
normally if it was entirely localized to non-DRM regions of the membrane? Answers to 
these questions will enhance our current understanding of how H-Ras interacts with these 
areas of the membrane. 
One good way to specifically localize a membrane protein to a region is by creating a 
chimeric, transmembrane protein. In this study a variant of the E 1 protein of the avian infec-
tious bronchitis virus was used as the transmembrane anchor for Ras (12). It was left to de-
termine the location of the chimeric protein in the membrane and its biological activity and 
answer at least some of the above stated questions. 
Materials and methods 
DNA 
The DNA ofEl(QI)-22-H Ras wt.3S (EHRwt) and El(QI)-22-H Ras 61L.3S 
(EHR61L) (12) were obtained from Berthe Willumsen (University of Copenhagen, Den-
mark) in pcDNAl (Invitrogen) and transferred to pcDNA3 (lnvitrogen). H-Ras is human and 
either has an activating Gln61Leu mutation (EHR61L) or the native sequence in that loca-
tion, as well as Cys 181 Ser, Cys l 84Ser and Cys 186Ser mutations, preventing posttransla-
tional modification of protein by isoprenoids. EHR wt was cut out ofpcDNAl using Hind III 
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and EcoR I and inserted into pcDNA3, which had been cut using the same restriction en-
zymes. EHR61L was made using site directed mutagenesis to mutate the endogenous Gln at 
position 61 to a Leu. The sense oligo used was 5' CTg gAT ACC gCC ggC CTg gAg gAg 
TAC AgC gCC 3' . The antisense oligo used was 5'ggC gCT gTA CTC CTC CAg gCC ggC 
ggT ATC CAg 3'. 
Other DNAs used include GFP H-Ras 61L, H-Ras 61L, H-Ras Ext61L (H-Ras 61L 
with a polybasic tail after the CAAX box and is known to localize in DRMs (2)), L YFP-GPI 
(A. Kenworthy, Vanderbilt), and GFP gt46 (A. Kenworthy, Vanderbilt). 
Cell culture 
NIH3T3 cells were grown in DMEM (Gibco) + 10% calf serum. 293T cells were 
grown in DMEM + 10% fetal bovine serum. PC-12 cells were grown in RPMI (Gibco) + 
I 0% heat inactivated horse serum + 5% fetal bovine serum. All cells were grown in 5% C02, 
except 293 T cells, which were grown in 10% C02. Stable NIH3 T3 cell lines were formed by 
a cotransfection of the appropriate DNA (GFP H-Ras 61L, EHR61L, or EHRwt) with pIRE-
Spuro (Clontech), an empty vector containing the gene for puromycin resistance. Puromycin 
was added after 48 hours at a concentration of I µg/mL. 
Antibodies 
Antibodies used for western blotting and immunofluorescence are: Ras l 46-3E4 
(Quality Biotech); Ras Yl3-238 (Santa Cruz); anti-caveolin (Transduction Laboratories); 
anti-transferrin receptor (Zymed Laboratories). Appropriate secondary antibodies were used 
(Molecular Probes). 
Transfection 
All transfections of PC-12 cells were performed using Lipofectamine (lnvitrogen) 
with 0.8µg of DNA per well of a 12-well plate coated with lOµg/mL laminin in PBS. For 
NIH3T3 and 293T cells other transfection reagents (Effectene and Superfect from Qiagen) 
were used according to their manufacturer' s recommendations. 
lmmunofluorescence 
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All cells were grown on coverslips coated with poly-L-lysine (lOOµg/mL) and/or fi-
bronectin (50µg/mL) in PBS. Cells were washed with PBS and then fixed with 4% parafor-
maldehyde for 5 minutes on ice. Cells were then permeabilized with cold methanol for 30 
seconds. Formaldehyde was quenched (1 % milk, l 50mM NaOAc in PBS, pH7) and cells 
were washed (1 % milk in PBS) before incubating in primary antibody (diluted 1 :400 in wash 
butter). Secondary antibodies were also diluted (1 :700) in wash buffer. After rinsing cells 
were mounted on microscope slides using 4µ1 Vectashield (Vectorlabs). 
Subcellular fractionation and density gradient membrane flotation 
Cells were lysed in hypotonic buffer (lmM Tris, pH 7.4; lmM MgCh in water) con-
taining protease inhibitors and broken up with a 26 gauge needle. The lysates were then spun 
at 4,000 rpm for 10 minutes at 4°C to remove the nuclei. SM NaCl was added to the super-
natant to a final concentration of l 50mM. The supernatant was then spun at 33,000 rpm for 
30 minutes to separate the cytosolic and membrane fractions. The Pl 00 (membrane bound) 
fraction was resuspended in water or 0.2% Triton X-100 on ice. If the pellet was resus-
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pended in Triton, it was spun again at 33,000 rpm and the SIOO and PlOO fractions were col-
lected. 
For a density gradient, the first membrane pellet was resuspended in Optiprep ( 40%) 
and sonicated. Triton was added to the fraction to a final concentration of 0.2%. Decreasing 
concentrations of Optiprep (from 3 7 .5% to 20%) were added carefully to the top of the sam-
ple. The gradient was then centrifuged at 4 °C for at least 16 hours at 30,000 rpm. Samples 
were concentrated with tricholoracetic acid and separated by SDS-PAGE. 
Western blot 
Cell lysates, S/P fractions or Optiprep gradient samples were run on SDS-PAGE (so-
dium dodecylsulfate polyacrylamide gel electrophoresis) gels. Unless otherwise noted, all 
samples were run on 15% gels. The gels were transferred to PVDF membrane for 40 min-
utes at 70 milliamps using a semi-dry transfer apparatus and were probed with the appropri-
ate antibody and detected by chemiluminescence. 
Soft agar assay 
A bottom layer of agar media (1 portion 1.8% agar:2 portions 2X NIH3T3 media, see 
Cell Culture) was plated in a 60mm tissue culture dish and left to set overnight. Then 
NIH3T3 cells (50,000 cells/mL) were suspended as single cells in normal media. 300µL of 
cells (15,000 cells) were added to lmL of agar media and carefully added to the base layer. 
All cell lines used were stably expressing the desired protein. Cells were counted on the 14th 
day after being plated and any clusters having two or more cells were counted as colonies. 
As a control, the stable cell lines were also examined by immunofluorescence and stained 
with DAPI and the percentage of cells expressing protein were then counted. 
Focus assay 
Focus assay experiments were performed by Berthe Willumsen and colleagues at the 
University of Copenhagen. 
Results 
Preparation of EHR61L and EHRwt 
The EHR wt DNA construct was received from Berthe Willumsen (University of Co-
penhagen) who had obtained it from the Donoghue lab that had constructed it originally ( 11 , 
12). EHR61L was designed in pcDNA3 from EHRwt by site directed mutagenesis (see Ma-
terials and Methods for details). Both constructs were sequenced and found to contain no 
inadvertent point mutations. Figure 3.1 , demonstrates the interactions ofH-Ras wt, H-Ras 
61L, H-Ras 61L-3S, EHRwt, and EHR61L. 
lmmunof/uorescence to determine localization 
Several different techniques were used to examine the EHR proteins and determine if 
they localized with DRMs. 293T cells expressing EHR61L or EHRwt, as well as L YFP-GPI 
(a known DRM marker), were treated with Triton X-100 before fixation and immunofluores-
cence. Cells were cotransfected with the GPI construct in order to ensure that DRMs were 
not disrupted while the rest of the membrane was solubilized. Results indicate that at 1 % 
Triton X-100 both EHR proteins were entirely extracted while the L YFP-GPI was retained 
(data not shown). Even at extremely low amounts of Triton X-100 (0.2%) both EHR61L and 
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Figure 3. 1 - lllustration, modified from Hart and Donoghue (12), ofH-Ras wt, H-Ras 61L, H-Ras 61L.3S, 
EHRwt, and EHR61L interacting with the plasma membrane. Due to its three serine mutations on its C-
terminus, H-Ras 61L-3S is unable to localize to the membrane. 
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Figure 3.2 - Transiently transfected 293T cells expressing either EHR61L or EHRwt (red) and LYFP-GPI 
(green). Cells were treated with either completely no Triton (CNT), as a control, or 0.2% Triton to extract non-
DRM regions of the membrane. 
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A similar experiment with NIH3T3 cells, using caveolin as the DRM marker, showed 
comparable results were obtained. Even at low percentages of Triton X-100 the transmem-
brane Ras was extracted while the caveolin remained intact (data not shown). Both of these 
experiments point to EHR61L and EHRwt being localized to non-DRM regions of the 
plasma membrane. 
Ultracentrifugation to determine localization 
Ultracentrifugation was used to confirm the non-DRM status of the EHR proteins. 
NIH3T3 cells that were stably expressing EHR61L or GFP H-Ras 61L (positive control) 
were spun to separate the cytosolic S 100 fractions from the membrane bound P 100 fractions. 
As expected the majority of each of the Ras proteins was found in the PlOO fraction (Figure 
3.3). This fraction was then treated with 0.2% Triton X-100 to solubilize non-DRM mem-
branes and separate them from those that are detergent resistant. Another high-speed spin 
was performed and the S 100 and P 100 fractions were collected. A western blot of the sam-
ples clearly indicates that EHR61L and GFP H-Ras 61L had been solubilized by the Triton 
while the caveolin (a DRM marker) was still membrane bound (Figure 3.3). EHR61L gives 
multiple bands due to its multiple glycosylation states. A similar experiment was done with 
EHR wt, giving the same results (data not shown). 
An additional ultracentrifugation technique was performed using sucrose gradients 
with Triton X-100. The gradients ranged from 40-20% sucrose with five intermediate pro-
gressions to allow for well defined separation of DRM and non-DRM proteins due to their 
buoyancy (DRMs) or lack thereof (non-DRM). As seen below in Figure 3.4, the DRM 
marker caveolin, which remains in DRMs, rose up to the least dense regions of the gradient, 
while EHR wt remained in the more dense regions. These same results were also seen with 
EHR61L (data not shown). This is consistent with what is expected from a non-DRM pro-


















Figure 3.3 - SIP fractionation of stable NIH3T3 cells expressing either EHR61L or GFP61 L. Lysates in the 
CNT (completely no Triton) lanes were separated in a standard S/P fractionation. The PlOO fraction of an iden-
tical fraction was then resuspended in 0.2% Triton and fractionated again. EHR61L has multiple bands due to 
its various glycosylation states. Blots were probed with transferrin receptor and caveolin to ensure that known 
non-DRM and DRM proteins, respectively, were in the proper locations. 
EHRvlt 
Caveol ~n 
Figure 3.4 - 293T cells expressing EHR wt were centrifuged at high speeds in order to separate DRM proteins 
from those which had been extracted with 0 .2% Triton. Caveolin was used as a DRM marker to ensure that 
DRMs remained intact. 
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Treatment of cells with cyclodextran to assess EHR localization 
Stable NIH3T3 cells expressing either EHR61 Lor EHRwt were transfected with 
L YFP-GPI and then treated with methyl-~-cyclodextran (MBCD) to absorb the cholesterol 
out of the plasma membrane and result in DRM disruption. Examination using a fluorescent 
microscope showed that L YFP-GPI had coalesced (Figure 3.58). The surprising observation 
was that distinct dark spots could be seen in the Ras staining (Figure 3.5A). It is interesting 
to note that these exactly corresponded with the GPI location (Figure 3.5C); EHR61L was 
specifically excluded from these clusters of GPI (Figure 3 .SA and B). While these results 
can not be fully explained, it is clear that EHR6 l L is acting in a very different manner than 
the DRM marker or the control (Figure 3.5 D and E). Once again lending support to the idea 
that EHR61L is not in a DRM. 
D. 
Figure 3.5 -2% cyclodextran was added to NIH3T3 cells expressing EHR61L to extract cholesterol from the 
plasma membrane and thus disrupt DRMs. EHR61L was detected using H-Ras 146 antibody and labeled red. 
L YFP-GPI is green and was used as a DRM maker. 
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Biological activity of EHR61L as seen in NIH3T3 cells 
The comparison of the morphology between the two stable cell lines, one expressing 
EHR61L and the other expressing EHRwt, provided some dramatic evidence for the biologi-
cal activity of EHR61 L. The EHR61 L cells were very long and spindle-shaped while the 
EHRwt cells were much more flat. The EHRwt cells would also cease cellular division upon 
contact with their neighbors in contrast to the EHR61 L cells which seemed to migrate to-
wards each other, preferring to grow atop one another. It is important to note that while there 
were distinct morphological differences between the EHR61L and the EHRwt, the transform-
ing ability of the EHR61L cells was decreased in comparison to their GFP H-Ras61L and H-
Ras Ext 61L counterparts (data not shown). 
Figure 3.6 - NIH3T3 cells stably expressing the labeled protein, colored green. The cells were also costained 
for caveolin, colored red. The morphologies of the EHR61L and the EHRwt are distinctly different in shape 
and behavior. The EHR.61 L also have a decrease in their expression of caveolin. 
Another interesting morphological feature of the EHR61 L stable cells is their down 
regulation of caveolin. According to several studies published in the late 1990's (8, 13), 
caveolin may be down regulated in transformed cells (see Figure 3.6 above). While we have 
not seen this in all transformed cell lines, there is a definite decrease in its expression in 
EHR61L cells. 
Biological activity of EHR61L as seen in PC-12 cells 
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Activated H-Ras has been. known to cause PC-12 cells to cease growth and differenti-
ate by sending out neurites ( 1 ). Thus, another test for the biological activity of the EHR pro-
teins was to see if it could cause differentiation in PC-12 cells. It is also important to com-
pare the phenotype of the cells after transfection as one means of determining if EHR is be-
having in a standard manner. 
In order to compare the cells, several standards were needed, these included nerve 
growth factor (NGF), H-Ras 61L and H-Ras Ext 61L. The neurites caused by H-Ras 61L are 
similar in shape and size to those caused by NGF (Figure 3.7) -- rather straight with only a 
few neurites per cell. Another important comparison is to H-Ras Ext 61L, an activated H-
Ras protein which is known to localize in DRMs (2). As seen in Figure 3.7, H-Ras Ext 61L 
causes a very different phenotype than either NGF or H-Ras 61L. The cell bodies are much 
broader with some ruffling of the edges and the neurites have dramatically more kinks. 
After transfecting cells with EHR6 l L clear neurites could be seen within 72 hours 
(Figure 3.7). These neurites were very different from those caused by NGF or H-Ras 61L, 
but appeared to be much more similar to those caused by H-Ras Ext 61L. This indicates that 
possibly a non-standard pathway is being activated and should be investigated further. 
EHRwt showed no differentiation (data not shown). 
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NGF Ext 61L 
GFP61L EHR61L 
Figure 3.7 - Typical cells after activation with NGF, or 4 days after transfection with H-Ras Ext61L, GFP H-
Ras 61L or EHR61L. 
Loss of anchorage-dependant growth 
NIH 3T3 cells that were stably expressing Ras were plated in soft agar in order to as-
sess their ability to grow in an anchorage-independent manner. Anchorage-independent 
growth is a hallmark of transformed cells, differing from normal culture-grown cells, which 
must be adherent to the bottom of the culture dish in order to grow. 
Three different stably expressing cell lines were plated in the soft agar, GFP H-Ras 
61L, EHR61L and EHR wt. The EHR wt formed a very low level of colonies (see Figures Sa 
and 9), 11.21 % of the cells showed growth. The EHR61L (Figures Sb and 9) and the GFP H-
Ras 61L (Figures Sc and 9) both showed comparable levels of growth in the soft agar, with 
59.15 % and 62.69%, respectively, of the cells growing after normalization based upon the 
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number of cells expressing the desired protein. Even though there was some growth seen in 
the EHRwt, the level is significantly lower than that of either activated Ras protein. It should 
also be noted that the colonies formed by EHR61L were smaller and slower growing than 
those from H-Ras 61L. 
A. B. C. 
EHRwt EHR61L GFP H-Ras 61 L 


















Soft Agar growth 
Figure 3.9 - Percentages of cells that grew in soft agar, after correction for the total number of cells expressing 
each protein. 
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Another assay for anchorage-independent growth is a focus assay. Transformed cells 
will continue to grow, even under confluent conditions, by growing on top of each other in a 
pile called a focus. Untransformed cells will be growth inhibited upon contact with 
neighboring cells. Thus it is possible to quantify the level of transformation by the amount 
foci and compare it to a standard. After transiently transfecting NIH3T3 cells with either v-
H-Ras (a viral, active form of H-Ras), EHR61L or EHR wt, the cells were allowed to grow. 
At a reasonable time point the foci were quantified and it was found that EHR6 l L formed a 
significant amount of foci , although the number of foci was less than those caused by H-Ras 
61L. EHRwt gave no foci. (personal communication, B. Willumsen) 
Discussion 
Based upon the above data, several important conclusions can be drawn. First is that 
both EHRwt and EHR61L localize to the plasma membrane, in non-DRM regions. Strong 
evidence supporting this has been seen in a number of different cell types, and by using mul-
tiple techniques. Both proteins behave exactly as one would expect of non-DRM proteins. 
Certainty of the localization of EHR proteins is vital for interpreting their biological 
activity. Despite its non-DRM status, EHR61L is biologically active. This was shown by 
morphology, anchorage-independent growth (soft agar and focus assays), and it's down regu-
lation of caveolin in NIH3 T3 cells, as well as the differentiation of PC-12 cells. In these 
ways, EHR61L is very similar to H-Ras 61L. 
While the activation seen by both EHR61L and H-Ras 61L is very similar, there are 
some significant differences. Cells expressing EHR6 l L are generally slower growing than 
their H-Ras 61 L counterparts. This was seen in both NIH3 T3 cells and PC-12 cells. In the 
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soft agar assay the EHR6 l L cell clumps were considerably smaller than those caused by H-
Ras 61 L. In PC-12 cells there was clear neurite formation, but it often took 24 hours longer 
to appear. 
The other major difference is in the phenotype of PC-12 cells after differentiation. H-
Ras 61L gives few, very straight neurites per cell. EHR61L on the other hand gives many 
outgrowths, most of which are kinked. This phenotype is much more similar to the one given 
by H-Ras Ext 61L. This in interesting since H-Ras Ext 61L is strongly associated with 
DRMs (2). This may imply that it is the cycling between DRM and non-DRM regions that is 
important for normal Ras functions. 
An interesting question was also answered by EHRwt. It is feasible that by perma-
nently localizing H-Ras in non-DRM regions of the membrane that the EHRwt protein could 
gain activity by not cycling between GTP and GDP bound states. This would mean that it 
would stay in the GTP bound form and thus become constitutively active. It turns out that 
this is not the case. There is no elevated level of activity of EHR wt over H-Ras wt. 
Even though Ras signaling may be aberrant when the protein is specifically excluded 
from DRMs, it is still present. This is important for understanding how Ras interacts with the 
plasma membrane and its microdomains. Any information we can glean about Ras and its 
role in the cell will eventually lead to the development of methods to help control its signal-
ing, and thus its sometimes disastrous effects on the human body. 
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CHAPTER 4: GENERAL CONCLUSIONS 
The study of Ras is important for the future treatment of diseases which are caused by 
its oncogenic counterparts. It is necessary to learn everything that can be learned about it in 
order to be able to best treat these life threatening diseases. One of the characteristics that 
researchers are still trying to grasp is that of the address of Ras. Just as it is important to 
know the address of a person to whom you wish to send a package, it is just as important to 
know the address of Ras if one desires to treat it. 
The research examined above in detail has been an attempt to look at a possible ad-
dress of H-Ras, in this case localization outside of DRMs. The question at hand is if H-Ras 
can live and work outside of the shelter of a DRM. While the first attempt at finding a non-
DRM was not successful, the EHR proteins definitively show that not only can H-Ras live 
outside of a DRM, but it thrives. EHR61L is able to do the same or similar work as its non-
transmembrane counterpart: the work of differentiating PC-12 cells, transforming NIH3 T3 
cells, growing foci and continuing to grow even upon placement in soft agar. 
The foundation has been laid for looking at Ras plasma membrane interactions on a 
much deeper level. From here it will be important to closely examine the Ras signaling 
pathways to determine what, if any, differences there between EHR61L, H-Ras 61L and Ext 
H-Ras 61L (a strong DRM Ras). One theory is that EHR61L is superactive. This can be 
looked by looking at the levels of phosphorylation of its downstream effectors. Ras activates 
many pathways, including at least one for apoptosis, so superactivity or preferential of an 
apoptotic pathway might explain why EHR61L lags behind H-Ras 61L in growth. One way 
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of looking at this would be to compare the number of G418 colonies formed by each protein. 
This would show if there is toxicity caused by the EHR protein. 
A solid foundation has been laid by this research into investigating the role of DRMs 
in Ras cellular function. From here it will be important to build upon that foundation and 
learn as much as we can about these interactions. It is through this learning that we will 
hopefully gain the knowledge needed to effectively treat human tumors that are caused by 
oncogenic Ras. 
